Skip to Main Content

Paper Details

A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.
Clin Cancer Res
19
2020
BRCA1, BRCA1 or, BRCA2, GATA6, HRD, Homologous Recombination-deficient Pancreatic Cancer, KRT17, Ki67, PARP, PARPi, PDAC, Pancreatic ductal adenocarcinoma, Patient, basal-like transcriptomic subtype, cisplatin, gBRCA, gBRCA-mutated, homologous recombination deficiency, mice, patient, patients, platinum, talazoparib, transcriptomic, xenografts
Author NameAffiliation
Robert E DenrocheOntario Institute for Cancer Research
Gun Ho JangOntario Institute for Cancer Research
Jean MonlongMcGill University
Mehdi MasoomianUniversity of Toronto
John M S BartlettOntario Institute for Cancer Research
John M S BartlettUniversity of Toronto
Julie M WilsonOntario Institute for Cancer Research
Celia M T GreenwoodMcGill University
Celia M T GreenwoodLady Davis Institute for Medical Research, Jewish General Hospital
Celia M T GreenwoodMcGill University
Celia M T GreenwoodMcGill University
Paz PolakIcahn School of Medicine at Mount Sinai Hospital
Paz PolakIcahn School of Medicine at Mount Sinai Hospital
William D FoulkesResearch Institute of the McGill University Health Centre
William D FoulkesMcGill University
William D FoulkesResearch Institute of the McGill University Health Centre
William D FoulkesMcGill University
Steven GallingerOntario Institute for Cancer Research
Steven GallingerPrincess Margaret Cancer Centre
  • 1 - 19

Datasets

Release 1.2